CombiGene AB (publ) has granted funding to establish a national cluster for commercialization of advanced therapies. The Centre for Commercialization of Regenerative Medicine (CCRM) Nordic will be located at GoCo Health Innovation City in Molndal. CCRM Nordic is backed by an industry consortium including CombiGene that will contribute to establishing the center as an organization with specialized infrastructure and expertise focused on Advanced Therapy Medicinal Product (ATMP) development, based on the successful CCRM model founded in Toronto, Canada.

The project is being coordinated by the recently formed not-for-profit CCRM Nordic AB (svb) and gathers engaged stakeholders to move the initiative forward. ATMP is the European Medicines Agency (EMA) classification of cell and gene therapy drugs, and tissue engineered drugs. These products must be produced to Good Manufacturing Practice (GMP) standards and complete clinical trials before applying for market approval and becoming available to patients.

Organizations like Canada's CCRM ensure ATMPs are manufactured and controlled according to the required quality standards, strengthening the chances these novel therapeutics will make it to patients. Mr. Wessberg has a background in stem cell science, GMP production and scientific services in the pharma industry. CCRM Nordic will accelerate commercialization of ATMPs and related technologies by providing specialized expertise and infrastructure.

The ambition is to collaborate with Nordic neighbors as well as being part of the CCRM Global international networks of hubs. CCRM Global is an alliance of international hubs operating to coordinate and optimize opportunities in the field of cell and gene therapies and regenerative medicine-based technologies.